Tag: ads

Ness Ziona, Israel, July 22, 2026 (GLOBE NEWSWIRE) -- Steakholder Foods Ltd. (Nasdaq: STKH), a global leader in 3D-printing technology for production of whole cuts of plant-based meat, today announced its plan to adjust the ratio of the company's American Depositary Shares (ADSs) in relation to its ordinary shares. The adjustment will change the current ratio from one (1) ADS representing four thousand (4,000) ordinary shares to a new ratio of one (1) ADS representing twelve thousand (12,000) ordinary shares, effective on July 27, 2026. Steakholder Foods' ADSs will continue to be traded on the Nasdaq Capital Market under the ticker "STKH," with an updated CUSIP Number of 583435508.

NEW YORK, June 26, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of UP Fintech Holding Limited (NASDAQ: TIGR) resulting from allegations that UP Fintech may have issued materially misleading business information to the investing public.

BEIJING, June 25, 2026 (GLOBE NEWSWIRE) -- DSC Holdings Ltd. (“DSC” or the “Company”) (NASDAQ: DSC), the AI application infrastructure for China’s used car industry, today announced that it has priced its initial public offering of 3,000,000 American depositary shares (“ADSs”) at US$17 per ADS, for a total offering size of approximately US$51 million, assuming the underwriters do not exercise their over-allotment option to purchase additional ADSs. Each ADS represents 20 Class A ordinary shares of the Company. The ADSs are expected to begin trading on the Nasdaq Global Market today under the ticker symbol “DSC.” The offering is expected to close on June 26, 2026, subject to customary closing conditions.

BRIDGEWATER, N.J., June 17, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech” or the “Company”), a global leader in cell therapy, today announced the pricing of an underwritten public offering of 7,700,000 American Depositary Shares (“ADSs”), each representing two ordinary shares of the Company, at a public offering price of $29.35 per ADS. In addition, Legend Biotech has granted the underwriters a 30-day option to purchase up to an additional 1,155,000 ADSs at the public offering price, less underwriting discounts and commissions. All of the ADSs are being offered by Legend Biotech. The gross proceeds to Legend Biotech from the offering, before deducting underwriting discounts and commissions and estimated offering expenses payable by Legend Biotech, are expected to be approximately $226 million, excluding any proceeds from the exercise of the underwriters’ option to purchase additional ADSs. The offering is expected to close on June 23, 2026, subject to customary closing conditions.

Integration with Viasat Ads unlocks premium in-flight advertising inventory through automated, data-driven buying

Introduces Industry-First Loyalty Program for All Customers with Cash Back in Verizon Dollars, Daily Surprises, and the End of Device Upgrade and Activation Fees

Uklon Store, Uklon’s first move into everyday commerce, opens with flower deliveries in Kyiv. Customers can buy a bouquet in a few taps and have it delivered the same day by Uklon drivers.